Clinical Trial Update: Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome [Phase 2]

View source ↗

Summary

A phase 2 rollover study evaluating continuing administration of NBI-98854 in pediatric Tourette Syndrome was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-04-19